Explore

Dignity Health to Open New Cancer Center in Redding, Expanding Treatment Access

Dignity Health to Open New Cancer Center in Redding, Expanding Treatment Access

Mercy Medical Center Redding is set to open a new regional cancer center in early September, enhancing access to cancer diagnosis and treatment in the Northstate. The facility will consolidate services such as laboratory testing, medical imaging, radiation treatment, and infusion therapy under one roof. The center will feature advanced equipment, including a PET-CT scanner and a new radiation therapy machine, and will expand infusion capacity from 12 to 31 chairs. The project, supported by major donors like Sierra Pacific Industries, aims to streamline patient care and reduce travel and wait times for treatment.

Creatine Supplement Shows Promise in Enhancing Cancer Immunotherapy

Creatine Supplement Shows Promise in Enhancing Cancer Immunotherapy

Recent research from the University of California, Los Angeles, published in iScience, has revealed that creatine, a common gym supplement, may significantly enhance the effectiveness of cancer immunotherapy. The study found that creatine acts as an energy source for dendritic cells, which are crucial in supporting and guiding killer T cells in the immune system's fight against cancer. While immunotherapies are powerful, they are only effective in 20-40% of patients. The research demonstrated that creatine supplementation could potentially improve the infrastructure supporting T cells, thereby boosting the immune response. The study involved testing creatine's effects in human cells and mouse models, showing promising results in slowing tumor growth and increasing dendritic cell activity. However, clinical trials are needed to confirm these findings in humans.

Sinai Hospital Unveils New Cancer Center to Enhance Patient Care

Sinai Hospital Unveils New Cancer Center to Enhance Patient Care

Sinai Hospital has opened the new Mandy and Dennis Weinman Cancer Building, a state-of-the-art facility aimed at improving cancer treatment and patient care. Dr. Pallavi Kumar, a medical oncologist, discussed the significance of the new center in an interview. The facility is part of LifeBridge Health's ongoing efforts to provide comprehensive cancer care. The new building is expected to offer advanced treatment options and support services for cancer patients, enhancing the hospital's ability to deliver personalized care. This development is seen as a significant step forward in the hospital's mission to improve health outcomes for cancer patients in the region.

Clinical Trial Offers New Hope for Pancreatic Cancer Patients with Innovative Chemotherapy Delivery

Clinical Trial Offers New Hope for Pancreatic Cancer Patients with Innovative Chemotherapy Delivery

Hernando Salcedo, an 83-year-old grandfather diagnosed with Stage III pancreatic cancer, has experienced significant improvements in his quality of life thanks to a clinical trial at the Miami Cancer Institute. The trial involves a novel chemotherapy delivery system developed by RenovoRX, which targets the tumor more precisely, reducing the severe side effects typically associated with traditional chemotherapy. The RenovoCath system uses a catheter with two balloons to deliver chemotherapy directly to the tumor site, minimizing exposure to the rest of the body. This method has shown to reduce adverse effects by 65% and increase survival by six months compared to standard chemotherapy. Salcedo, who was not a candidate for surgery, opted for this trial after experiencing debilitating side effects from conventional treatment. Since participating, his cancer has stabilized, allowing him to regain weight, energy, and participate in family activities.

Miami Cancer Institute's Clinical Trial Offers Hope for Late-Stage Pancreatic Cancer Patients

Miami Cancer Institute's Clinical Trial Offers Hope for Late-Stage Pancreatic Cancer Patients

Hernando Salcedo, an 83-year-old grandfather, was diagnosed with Stage III pancreatic cancer in May 2025. After experiencing severe side effects from traditional chemotherapy, Salcedo was presented as a candidate for a clinical trial at the Miami Cancer Institute. The trial involved a new chemotherapy delivery device from RenovoRX, designed to target the tumor more precisely and reduce side effects. The RenovoCath system uses a catheter to deliver chemotherapy directly to the tumor, minimizing exposure to the rest of the body. This method has shown to reduce adverse effects and increase survival rates. Salcedo participated in the trial and reported significant improvements in his quality of life, experiencing fewer side effects compared to traditional chemotherapy.

Kobe University Develops Mass-Produced iPSC-Derived T Cells for Colorectal Cancer Treatment

Kobe University Develops Mass-Produced iPSC-Derived T Cells for Colorectal Cancer Treatment

Researchers at Kobe University have successfully developed mass-producible induced pluripotent stem cell (iPSC)-derived gamma delta T cells (γδT cells) that have shown promise in suppressing tumor growth in preclinical models of colorectal cancer (CRC). The study, published in Stem Cell Reports, highlights the potential of these cells to offer a faster and more cost-effective alternative to current cancer immunotherapies. Unlike autologous CAR T-cell therapies, which are expensive and time-consuming, the iPSC-derived γδT cells can be produced off-the-shelf and used across different patients. This development could significantly impact the treatment of CRC, a highly heterogeneous cancer, by providing a more accessible and scalable immunotherapy option.

CRISPR Technology Enhances Prostate Cancer Immunotherapy by Increasing Tumor Vulnerability

CRISPR Technology Enhances Prostate Cancer Immunotherapy by Increasing Tumor Vulnerability

Researchers have developed an experimental RNA targeting technology using CRISPR that may significantly improve the effectiveness of immunotherapy in treating prostate cancer. Prostate tumors are typically 'immune cold,' meaning they attract few T cells, which are crucial for the success of immunotherapy. The new CRISPR-based tool modifies RNA within prostate cancer cells, making the tumors more visible to immune cells. This advancement was detailed in a study published in Nature Biomedical Engineering, where the technology was shown to enhance the response of prostate tumors to immune checkpoint therapy in mice. The study, led by scientists from Duke University School of Medicine, demonstrated that the CRISPR tool could restore the MHC-1 complex, a molecular signal that helps T cells recognize tumor cells, thereby increasing the effectiveness of immunotherapy.

Testosterone Replacement Therapy and Its Impact on Prostate Cancer Risk

Testosterone Replacement Therapy and Its Impact on Prostate Cancer Risk

Testosterone replacement therapy (TRT) is being used to treat symptoms of hypogonadism, such as decreased libido and energy levels. Concerns have been raised about the potential for TRT to promote prostate cancer, especially in individuals with a history of the disease. Recent studies, however, suggest that TRT may not lead to cancer progression in these patients. Research is ongoing, with several randomized control trials examining the effects of TRT in various prostate cancer treatment settings. These studies aim to determine the safety and efficacy of TRT in men with a history of prostate cancer, particularly in improving erectile function post-treatment.

Kobe University Develops iPSC-Derived T Cells for Colorectal Cancer Treatment

Kobe University Develops iPSC-Derived T Cells for Colorectal Cancer Treatment

Researchers at Kobe University have developed a method to mass-produce induced pluripotent stem cell (iPSC)-derived gamma delta T cells (γδT cells) that show promise in treating colorectal cancer (CRC). In a preclinical study, these cells were able to significantly reduce tumor growth in mouse models. The study, published in Stem Cell Reports, highlights the potential of these cells as a faster and more cost-effective alternative to current autologous CAR T-cell therapies, which are limited by high costs and time-consuming processes. The γδT cells can be harvested from donors and used across different patients, offering a promising off-the-shelf solution for cancer immunotherapy.

Johnson Johnson's Multiple Myeloma Therapies Show Promising Phase 3 Results

Johnson Johnson's Multiple Myeloma Therapies Show Promising Phase 3 Results

Johnson Johnson's Multiple Myeloma Therapies Show Promising Phase 3 Results

Endeavor Health's $175M Cancer and Neurological Center Approved, Enhancing Patient Care in Arlington Heights

Endeavor Health's $175M Cancer and Neurological Center Approved, Enhancing Patient Care in Arlington Heights

Endeavor Health Northwest Community Hospital has received approval from a state board to proceed with the construction of a new $175 million cancer and neuroscience center. The planned three-story, 104,000-square-foot facility will consolidate the hospital's outpatient cancer and neurological care services. This development is part of a broader trend among Chicago-area healthcare systems to expand cancer care in response to increasing demand. The hospital's application cites a projected 12% increase in cancer incidence in the area by 2028. The new center aims to provide a more cohesive and coordinated care experience by centralizing services, reducing travel for patients, and increasing access to clinical trials. The Illinois Health Facilities and Services Review Board unanimously approved the project, which now awaits approval from the village of Arlington Heights.

Sinai Hospital Opens New Cancer Center to Enhance Patient Care

Sinai Hospital Opens New Cancer Center to Enhance Patient Care

Sinai Hospital has inaugurated the Mandy and Dennis Weinman Cancer Building, a new facility dedicated to cancer treatment and research. Dr. Pallavi Kumar, a medical oncologist, discusses the center's capabilities and its role in providing comprehensive care to cancer patients. Sponsored by LifeBridge, the center aims to offer state-of-the-art treatment options and support services, enhancing the hospital's ability to address the needs of the community. The opening of this facility marks a significant advancement in the hospital's commitment to improving healthcare outcomes for cancer patients.